
Annual report 2025
added 04-25-2026
Aurora Cannabis Net Income 2011-2026 | ACB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -695 M | -3.28 B | -291 M | 71.9 M | -13 M | -5.72 M | -9.52 M | -400 K | -393 K | -316 K | -322 K |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.9 M | -3.28 B | -384 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M | ||
|
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
-73.1 M | $ 2.68 | - | $ 1.37 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 4.06 | - | $ 57.1 M | ||
|
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | ||
|
Solid Biosciences
SLDB
|
-174 M | $ 7.92 | - | $ 693 M | ||
|
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 1.14 | - | $ 1.41 M | ||
|
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | ||
|
Tilray
TLRY
|
-1.45 B | $ 6.75 | - | $ 4.17 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | ||
|
Veru
VERU
|
-37.8 M | $ 2.32 | 0.43 % | $ 313 M | ||
|
Bausch Health Companies
BHC
|
-592 M | $ 5.63 | - | $ 2.05 B | ||
|
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | ||
|
Viatris
VTRS
|
54.7 M | $ 14.59 | - | $ 17.5 B | ||
|
Canopy Growth Corporation
CGC
|
-598 M | $ 1.19 | - | $ 128 M | ||
|
Harrow Health
HROW
|
-5.14 M | $ 39.7 | - | $ 1.46 B | ||
|
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-131 M | $ 1.45 | - | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
861 K | $ 2.35 | - | $ 309 M | ||
|
Evolus
EOLS
|
-51.6 M | $ 5.3 | - | $ 342 M | ||
|
Sundial Growers
SNDL
|
-230 M | $ 1.51 | - | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
-760 M | $ 8.03 | - | $ 411 M | ||
|
Pacira BioSciences
PCRX
|
-99.6 M | $ 24.51 | - | $ 1.13 B | ||
|
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | ||
|
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
-153 K | $ 1.01 | - | $ 4.36 M | ||
|
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | ||
|
Assertio Holdings
ASRT
|
-30.4 M | $ 18.04 | - | $ 116 M | ||
|
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-57.4 M | $ 7.21 | - | $ 285 M | ||
|
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-8.61 M | $ 1.02 | -2.86 % | $ 50.9 M | ||
|
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | ||
|
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-5.31 M | $ 0.87 | 1.99 % | $ 31.3 M | ||
|
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.63 | - | $ 2.7 M | ||
|
TherapeuticsMD
TXMD
|
-569 K | $ 2.19 | 0.46 % | $ 25.3 M |